PERFORMANCE RIGHTS APPROVED BY SHAREHOLDERS

Lynas Corporation Ltd (ASX:LYC, OTC:LYSDY) confirms that, during the AGM held on 26 November 2019, Shareholders approved Resolution 3 relating to a proposed award of Performance Rights. As set out in the 2019 AGM Notice, the Performance Rights that are now being awarded in accordance with Resolution 3 are as follows:

1. 109,148 FY19 STI performance rights for the benefit of Amanda Lacaze, the Lynas CEO and Managing Director. This award of STI Performance Rights arose from satisfaction of performance hurdles relating to FY19. The performance hurdles that were satisfied in FY19 related to NdPr production volume and team / individual performance. The STI Performance Rights have a 1 year vesting period. Further detail is provided in the remuneration report section of the FY19 financial report and in the 2019 AGM Notice.

2. 436,592 LTI Performance Rights for the benefit of Amanda Lacaze. The LTI Performance Rights have a three year vesting period and they are subject to vesting conditions relating to EBIT growth, Total Shareholder Return and Lynas 2025 Growth Project targets over the next three years. Further details are provided in the 2019 AGM Notice.

In addition, the Lynas team managing the Lynas 2025 Growth project has expanded to include new personnel. The Lynas Board has approved an award of 34,203 LTI Performance Rights to a new senior manager on the same terms as were set out in the Lynas ASX announcement dated 2 September 2019. The LTI Performance Rights have a three year vesting period and they are subject to vesting conditions relating to the Lynas 2025 Growth Project targets over the next three years. Further details were provided in section 2 of the Lynas ASX announcement dated 2 September 2019.

Attached is an Appendix 3B concerning the above awards of Performance Rights.

For all media enquiries please contact Jennifer Parker or Lauren Stutchbury from Cannings Corporate Communications on +61 2 8284 9990.

Andrew Arnold
Company Secretary
Appendix 3B

New issue announcement,
application for quotation of additional securities
and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity
LYNAS CORPORATION LTD

ABN
27 009 066 648

We (the entity) give ASX the following information.

Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).

1. Class of securities issued or to be issued
   Unlisted Performance Rights

2. Number of securities issued or to be issued (if known) or maximum number which may be issued
   579,943

3. Principal terms of the securities (eg, if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion)
   The Employee Performance Rights are subject to the Performance Conditions specified in the Lynas AGM Notice 2019 and are exercisable without further consideration on the dates specified in section 9
Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Issue price or consideration

The Performance Rights were valued at $2.3930 per Performance Right.

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

To be granted for the benefit of the senior managers of the Company on the basis set out in the Lynas AGM Notice 2019 and in the attached ASX announcement.

Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i

The date the security holder resolution under rule 7.1A was passed

Number of *securities issued without security holder approval under rule 7.1

Number of *securities issued with security holder approval under rule 7.1A

+ See chapter 19 for defined terms.
6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

6f Number of securities issued under an exception in rule 7.2

6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7 Dates of entering *securities into uncertificated holdings or despatch of certificates

The Performance Rights will be granted with effect from the date of Board approval of the proposed grant of Performance Rights, being 26 August 2019.

8 Number and *class of all *securities quoted on ASX (including the securities in section 2 if applicable)

<table>
<thead>
<tr>
<th>Number</th>
<th>*Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>695,378,577</td>
<td>Ordinary shares</td>
</tr>
<tr>
<td>Number</td>
<td><code>Class</code></td>
</tr>
<tr>
<td>--------</td>
<td>---------</td>
</tr>
<tr>
<td>1,830,247</td>
<td>LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 18 September 2018 to 18 September 2020</td>
</tr>
<tr>
<td>997,490</td>
<td>LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 30 August 2019 to 30 August 2021</td>
</tr>
<tr>
<td>900,336</td>
<td>LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 28 August 2020 to 28 August 2022</td>
</tr>
<tr>
<td>690,004</td>
<td>LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 31 August 2021 to 31 August 2023</td>
</tr>
<tr>
<td>426,737</td>
<td>STI Performance Rights exercisable for no further consideration in the first employee trading window after 26 August 2020</td>
</tr>
<tr>
<td>1,446,970</td>
<td>LTI Performance Rights exercisable for no further consideration, subject to vesting conditions, in the period 26 August 2022 to 26 August 2024</td>
</tr>
<tr>
<td>13,652,135.93</td>
<td>US$13,652,135.93 of Convertible Bonds at 1.875% p.a. maturing 30 September 2020, convertible at A$1.00 per share based on an exchange rate of A$1.00 = US$0.75. Fractions of a share are rounded down on conversion.</td>
</tr>
</tbody>
</table>

| 10 | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) | N/A |

**Part 2 - Bonus issue or pro rata issue**

| 11 | Is security holder approval required? |

+ See chapter 19 for defined terms.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Is the issue renounceable or non-renounceable?</td>
</tr>
<tr>
<td>13</td>
<td>Ratio in which the securities will be offered</td>
</tr>
<tr>
<td>14</td>
<td>Class of securities to which the offer relates</td>
</tr>
<tr>
<td>15</td>
<td>Record date to determine entitlements</td>
</tr>
<tr>
<td>16</td>
<td>Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?</td>
</tr>
<tr>
<td>17</td>
<td>Policy for deciding entitlements in relation to fractions</td>
</tr>
</tbody>
</table>
| 18 | Names of countries in which the entity has security holders who will not be sent new issue documents   
   Note: Security holders must be told how their entitlements are to be dealt with.  
   Cross reference: rule 7.7. |
<p>| 19 | Closing date for receipt of acceptances or renunciations |
| 20 | Names of any underwriters |
| 21 | Amount of any underwriting fee or commission |
| 22 | Names of any brokers to the issue |
| 23 | Fee or commission payable to the broker to the issue |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>If the issue is contingent on security holders’ approval, the date of the meeting</td>
</tr>
<tr>
<td>26</td>
<td>Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled</td>
</tr>
<tr>
<td>27</td>
<td>If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders</td>
</tr>
<tr>
<td>28</td>
<td>Date rights trading will begin (if applicable)</td>
</tr>
<tr>
<td>29</td>
<td>Date rights trading will end (if applicable)</td>
</tr>
<tr>
<td>30</td>
<td>How do security holders sell their entitlements in full through a broker?</td>
</tr>
<tr>
<td>31</td>
<td>How do security holders sell part of their entitlements through a broker and accept for the balance?</td>
</tr>
<tr>
<td>32</td>
<td>How do security holders dispose of their entitlements (except by sale through a broker)?</td>
</tr>
<tr>
<td>33</td>
<td>*Despatch date</td>
</tr>
</tbody>
</table>

+ See chapter 19 for defined terms.
Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities.

34  Type of securities
    *(tick one)*

(a)  ☐ Securities described in Part 1

(b)  ☐ All other securities
    Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35  ☐ If the securities are equity securities, the names of the 20 largest holders of the additional securities, and the number and percentage of additional securities held by those holders

36  ☐ If the securities are equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories

1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37  ☐ A copy of any trust deed for the additional securities

Entities that have ticked box 34(b)

38  ☐ Number of securities for which quotation is sought

39  ☐ Class of securities for which quotation is sought
40 Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?

If the additional securities do not rank equally, please state:
- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now
Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)

42 Number and class of all securities quoted on ASX (including the securities in clause 38)

<table>
<thead>
<tr>
<th>Number</th>
<th>‘Class</th>
</tr>
</thead>
</table>

+ See chapter 19 for defined terms.
Quotation agreement

1. Quotation of our additional *securities is in ASX’s absolute discretion. ASX may quote the *securities on any conditions it decides.

2. We warrant the following to ASX.
   - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
   - There is no reason why those *securities should not be granted *quotation.
   - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
     Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
   - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
   - If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

3. We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4. We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before *quotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:  
Company Secretary)  
Date: 27 November 2019  
Print name: ANDREW ARNOLD

+ See chapter 19 for defined terms.